Synonyms: Careram® | Iremod | Kolbet® | T-614
iguratimod is an approved drug (China (2011), Japan (2012))
Compound class:
Synthetic organic
Comment: Iguratimod is a methanesulfonanilide disease-modifying anti-rheumatic drug [1,5-6]. Evidence from a mouse colitis model shows an anti-inflammatory effect of iguratimod, partly via regulation of Th17/Treg cells [4], that suggest iguratimod as a novel therapeutic for the treatment of IBD.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Aikawa Y, Yamamoto M, Yamamoto T, Morimoto K, Tanaka K. (2002)
An anti-rheumatic agent T-614 inhibits NF-kappaB activation in LPS- and TNF-alpha-stimulated THP-1 cells without interfering with IkappaBalpha degradation. Inflamm Res, 51 (4): 188-94. [PMID:12058956] |
2. Bloom J, Metz C, Nalawade S, Casabar J, Cheng KF, He M, Sherry B, Coleman T, Forsthuber T, Al-Abed Y. (2016)
Identification of Iguratimod as an Inhibitor of Macrophage Migration Inhibitory Factor (MIF) with Steroid-sparing Potential. J Biol Chem, 291 (51): 26502-26514. [PMID:27793992] |
3. Greven D, Leng L, Bucala R. (2010)
Autoimmune diseases: MIF as a therapeutic target. Expert Opin Ther Targets, 14 (3): 253-64. [PMID:20148714] |
4. Jiang XP, Huang XL, Yang ZP, Wang SC, Xie W, Miao L, Tang L, Huang ZM. (2018)
Iguratimod ameliorates inflammatory responses by modulating the Th17/Treg paradigm in dextran sulphate sodium-induced murine colitis. Mol Immunol, 93: 9-19. [PMID:29121519] |
5. Luo Q, Sun Y, Liu W, Qian C, Jin B, Tao F, Gu Y, Wu X, Shen Y, Xu Q. (2013)
A novel disease-modifying antirheumatic drug, iguratimod, ameliorates murine arthritis by blocking IL-17 signaling, distinct from methotrexate and leflunomide. J Immunol, 191 (10): 4969-78. [PMID:24123677] |
6. Mucke HA. (2012)
Iguratimod: a new disease-modifying antirheumatic drug. Drugs Today, 48 (9): 577-86. [PMID:23032798] |